Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.67 |
| ▸ | CALM1 | P0DP23 | 2/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.51 |
| ▸ | CMA1 | P23946 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7357999 | 0.89 | TAAR1 (0.62) | TAAR1CALM1CYP3A4SLC6A4CYP1A2 | |
| SCHEMBL5657606 | 0.88 | TAAR1 (0.52) | TAAR1CALM1MAPTCYP2D6ALDH1A1 | |
| SCHEMBL108087 | 0.87 | TAAR1 (0.77) | TAAR1CALM1CYP3A4SLC6A4CYP1A2 | |
| SCHEMBL11555889 | 0.85 | TAAR1 (0.59) | TAAR1CALM1CYP3A4SLC6A4CYP1A2 | |
| SCHEMBL16399861 | 0.84 | TAAR1 (0.67) | TAAR1CALM1CYP3A4SLC6A4CYP1A2 | |
| SCHEMBL4579616 | 0.83 | TAAR1 (0.60) | TAAR1CALM1CYP3A4SLC6A4CYP1A2 | |
| SCHEMBL108050 | 0.83 | CALM1 (0.72) | TAAR1CALM1CYP3A4SLC6A4CYP1A2 | |
| SCHEMBL11399822 | 0.83 | TAAR1 (0.56) | TAAR1CALM1CYP3A4SLC6A4CYP1A2 | |
| SCHEMBL11399820 | 0.83 | TAAR1 (0.56) | TAAR1CALM1CYP3A4SLC6A4CYP1A2 | |
| SCHEMBL16606276 | 0.82 | TAAR1 (0.46) | TAAR1CALM1CYP2D6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170240558-A1 | SANGUINARINE ANALOG PP2C INHIBITORS FOR CANCER TREATMENT | LIXTE BIOTECHNOLOGY, INC. (US) | 2017-08-24 | — | — | US | disclosed |
| US-20170240558-A1 | SANGUINARINE ANALOG PP2C INHIBITORS FOR CANCER TREATMENT | LIXTE BIOTECHNOLOGY, INC. (US) | 2017-08-24 | — | — | US | disclosed |
| US-20160009727-A1 | SANGUINARINE ANALOG PP2C INHIBITORS FOR CANCER TREATMENT | LIXTE BIOTECHNOLOGY, INC. (US) | 2016-01-14 | — | — | US | disclosed |
| US-20160009727-A1 | SANGUINARINE ANALOG PP2C INHIBITORS FOR CANCER TREATMENT | LIXTE BIOTECHNOLOGY, INC. (US) | 2016-01-14 | — | — | US | disclosed |
| WO-2014149494-A1 | SANGUINARINE ANALOG PP2C INHIBITORS FOR CANCER TREATMENT | LIXTE BIOTECHNOLOGY, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2010104929-A1 | SULFONAMIDE CONTAINING COMPOUNDS AND USES THEREOF | ELIXIR PHARMACEUTICALS, INC. (US) | 2010-09-16 | — | — | WO | disclosed |
| US-7208517-B1 | Endothelin antagonists | ABBOTT LABORTORIES (US) | 2007-04-24 | — | — | US | disclosed |
| EP-0256888-B1 | BENZOTHIAZEPINE VASODILATORS HAVING ARALKYL SUBSTITUTION | McNeilab, Inc. (US) | 1991-07-03 | — | — | EP | disclosed |
| US-4729994-A | Benzothiazepine vasodilators having aralkyl substitution | MCNEILAB, INC. (US) | 1988-03-08 | — | — | US | disclosed |
| EP-0256888-A1 | Benzothiazepine vasodilators having aralkyl substitution | McNeilab, Inc. (US) | 1988-02-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160009727-A1 | SANGUINARINE ANALOG PP2C INHIBITORS FOR CANCER TREATMENT | PPP2R2A, PPP2R1A, PPP1R7 | TAAR1 3326/4885CALM1 350/4885CYP3A4 4384/4885 |
| US-20170240558-A1 | SANGUINARINE ANALOG PP2C INHIBITORS FOR CANCER TREATMENT | PPP2R2A, PPP2R1A, PPP1R7 | TAAR1 3326/4885CALM1 350/4885CYP3A4 4384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.